drugset / Trial / NCT00023998

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

NCT00023998

Phase 2 Completed 80 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. Phase II trial to study the effectiveness of chemotherapy with or without trastuzumab in treating patients who have metastatic osteosarcoma

Timeline

Start
2001-07
Primary completion
2005-11
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Monoclonal antibody Intravenous
Background Cisplatin Other / unclassified Intravenous
Background Doxorubicin Other / unclassified Intravenous
Background Etoposide Small molecule Intravenous
Background Ifosfamide Small molecule Intravenous
Background Leucovorin Small molecule Intravenous
Background Methotrexate Small molecule Intravenous
Background filgrastim Protein / enzyme biologic Intravenous

Indications